Name | Bromisoval |
Synonyms | Bromisoval Bromvaletone Bromisovalum Bromvalerylurea BROMOVALERYLUREA BROMOISOVALERYLUREA RARECHEM AX KI 5046 LABOTEST-BB LT00134620 A-(BROMOISOVALERYL)UREA 1-(2-BROMOISOVALERYL)UREA ALPHA(BROMOISOVALERYL)UREA BROMO-ISO-VALERYLUREA (ALPHA) 2-bromo-N-carbamoyl-3-methylbutanamide (2S)-2-bromo-N-carbamoyl-3-methylbutanamide (2R)-2-bromo-N-carbamoyl-3-methylbutanamide |
CAS | 496-67-3 |
EINECS | 207-825-7 |
InChI | InChI=1/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)/t4-/m0/s1 |
InChIKey | CMCCHHWTTBEZNM-UHFFFAOYSA-N |
Molecular Formula | C6H11BrN2O2 |
Molar Mass | 223.07 |
Density | 1.6005 (rough estimate) |
Melting Point | 152 °C |
Water Solubility | 19.03g/L(temperature not stated) |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Merck | 14,1397 |
pKa | 10.54±0.70(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.5410 (estimate) |
Physical and Chemical Properties | White needle-like crystals. Melting point 147-149 ℃, soluble in alcohol, ether, acetone, insoluble in cold water. Soluble in hot water. No odor, slightly bitter taste. |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval. Bromisoval and rotenone reduce intracellular ATP (iATP) levels to a similar extent. A combination of rotenone and filgotinib suppress NO release in LPS-treated BV2 cells as strongly as Bromisoval. |
In vivo study | Bromisoval (Bromvaletone) and carbromal are the most potent central depressants within each series. Depressant activities (ISD 50 values) and acute toxicities (LD 50 values) in male mice after intraperitoneal injection of Bromisoval are 0.35 (0.30-0.39) and 3.25 (2.89-3.62) mmol/kg, respectively. |
RTECS | YS3150000 |
Toxicity | LD50 in male mice (mmoles/kg): 3.25 i.p. (Mrongovius) |